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BCOMMENTARY
igh Unbound Mycophenolic Acid Concentrations in
Hematopoietic Cell Transplantation Patient with
epsis and Renal and Hepatic Dysfunction
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hMycophenolate mofetil (MMF) is commonly used
n patients undergoing allogeneic hematopoietic cell
ransplantation (HCT) for enhancement of engraft-
ent and graft-versus-host disease prophylaxis. MMF
s a prodrug that is converted to the active moiety,
ycophenolic acid (MPA), in the gut wall, blood, and
iver. MPA is then glucuronidated to the primary
nactive metabolite, MPAG, in the liver and kidney.
PA and MPAG are highly protein-bound to plasma
lbumin [1]. Because only unbound MPA exerts a
harmacologic effect, illnesses that result in decreased
rotein binding may lead to high concentrations of
nbound MPA and to adverse effects.
A 36-year-old woman presented for myeloablative
mbilical cord blood transplantation (total nucleated
ell dose 0.28  108/kg) for severe myelodysplastic
yndrome. Conditioning was performed with ﬂudara-
ine, cyclophosphamide, and total body irradiation.
rophylactic MMF 1 g every 12 hours intravenously
IV) and cyclosporine 2.5 mg/kg every 12 hours IV
as begun on day 3. On day 1, the patient became
ebrile, and vancomycin, ceftazidime, and tobramycin
ere initiated. Blood cultures tested positive for multire-
istant Escherichia coli. On day4, the patient developed
eptic shock and oliguric acute renal failure. She was
ntubated, and continuous venovenous dialysis was
egun (Prisma; Gambro Healthcare, Stockholm, Swe-
en) on day 5. All nephrotoxins and immunosup-
ressants were withheld. Multiple organ failure pro-
ressed to include hepatic shock and disseminated
ntravascular coagulation. On days 6 and 8, MMF
0.5 g every 12 hours IV) and cyclosporine, respec-
ively, were restarted at reduced doses to promote
ngraftment. The patient had transient clinical im-
rovement and was extubated on day22. Prisma was
iscontinued, and hemodialysis was initiated. On day
25, the patient was reintubated as a result of respi-
atory insufﬁciency secondary to progressive nodular
nﬁltrates of the lungs. Despite full support, the pa-
ient’s clinical condition deteriorated, and on day 29
he was removed from life support. At the time of
eath, her white blood cell count was 0.1  109/L. n
B&MTPharmacokinetic sampling was performed on day
8, and total MPA trough and area under the curve
-12 (AUC0-12) were 2.4 g/mL and 58.33 g · h/
L, respectively. Unbound MPA trough and AUC0-12
ere 0.049 g/mL and 1.67 g · h/mL, respectively.
n the day of pharmacokinetics sampling, her serum
reatinine was 2.97 mg/dL, total bilirubin was 19.8
g/dL, aspartate aminotransferase was 1931 U/L, ala-
ine aminotransferase was 2383 U/L, and white blood
ell count was 0.4  109/L. Her albumin was 2.8
/dL on day 5 before fresh frozen plasma and cryo-
recipitate.
Despite oliguric renal failure and severe hepatic
nsufﬁciency, the total MPA trough and AUC0-12 were
ithin normal limits, albeit in the high normal range
stablished for organ transplantation, with the 50%
MF dose reduction. However, the unbound MPA
rough and AUC0-12 were 5- to 10-fold higher than
ormal. In HCT patients, typical unbound trough and
UC0-12 with 1 g every 12 hours are 0.005 g/mL and
.3 g · h/mL, respectively (data in press). Dosing
uidelines for MMF in patients with renal and hepatic
ysfunction are limited. The manufacturer recom-
ends no dose reductions in patients with hepatic
arenchymal disease and doses no greater than 1 g
very 12 hours in patients with severe renal dysfunc-
ion (glomerular ﬁltration rate25 mL/min/1.73 m2).
MF is not removed by hemodialysis [1,2] and is
nlikely to be removed by Prisma, although no pub-
ished data are available. Given that MPA is glucu-
onidated in the liver and kidney, dose reductions in
he setting of hepatic plus renal failure are reasonable.
he excessively increased unbound concentrations
bserved in this patient were likely due to altered
rotein binding secondary to sepsis, severe organ dys-
unction, and hypoalbuminemia.
The consequences of increased MPA concentra-
ions in HCT have not been determined; however, in
rgan transplantation, an unbound MPA AUC0-12
0.4 g · h/mL is associated with an increased risk of
eutropenia and infection [3]. Severe MMF toxicity
as been reported in organ transplant recipients with
ormal total MPA concentrations but dramatically
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9ncreased unbound concentrations [4,5]. In kidney
ransplantation, an albumin concentration 3.1 g/dL
s associated with a signiﬁcantly higher likelihood of
aving abnormally increased unbound MPA concen-
rations [6].
This case supports a need for therapeutic moni-
oring of MPA, particularly unbound concentrations,
n critically ill patients. Despite a 50% dose reduction,
nbound MPA exposure was still up to 10-fold higher
han expected. The potential for hematologic adverse
ffects and a greater propensity toward infections due
o increased unbound MPA concentrations should be
arefully considered in HCT patients with organ dys-
unction.
EFERENCES
. CellCept [package insert]. Nutley, NJ: Roche Laboratories;
1998.
. Macphee IA, Speaﬁco S, Bewick M, et al. Pharmacokinetics of
mycophenolate mofetil in patients with end-stage renal failure.
Kidney Int. 2000;57:1164-1168.
. Weber LT, Shipkova M, Armstrong V, et al. The pharmacoki-
netic-pharmacodynamic relationship for total and free mycophe-
nolic acid in pediatric renal transplant recipients: a report of the
German Study Group on Mycophenolate Mofetil Therapy.
J Am Soc Nephrol. 2002;13:759-768.
. Mudge DW, Atcheson BA, Taylor PJ, Pillans PI, Johnson DW.
Severe toxicity associated with a markedly elevated mycophenolic
acid free fraction in a renal transplant recipient. Ther Drug
Monit. 2004;26:453-455. M
78. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM.
Decreased protein binding of mycophenolic acid associated with
leukopenia in a pancreas transplant recipient with renal failure.
Transplantation. 1998;65:1127-1129.
. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophe-
nolic acid should be monitored in renal transplant recipients
with hypoalbuminemia. Ther Drug Monit. 2004;25:284-286.
amala Jacobson, PharmD1,2,3
anel Long, BS1
ohn Rogosheske, PharmD4
laudio Brunstein, MD2,3,5
aniel Weisdorf, MD2,3,5
Experimental and Clinical Pharmacology
ollege of Pharmacy
niversity of Minnesota
inneapolis, Minnesota
Division of Hematology
ncology and Transplantation
niversity of Minnesota
chool of Medicine
inneapolis, Minnesota
University of Minnesota Cancer Center
inneapolis, Minnesota
Department of Pharmacy
airview University Medical Center
inneapolis, Minnesota
Blood and Marrow Transplant Program
niversity of Minnesota
inneapolis, Minnesota
